Vertex Looks Attractive With New Positive Data, Acquisition Buzz
- Vertex is solidifying its position in the Cystic Fibrosis market with positive early stage data.
- The company is deemed to be a potential acquisition target.
- Vertex raised its revenue guidance for Kalydeco, signaling strong performance.
By S. Mitra
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) develops therapies for serious and orphan diseases. It particularly focuses on the Cystic Fibrosis market, where it has already carved a niche. The company has two drugs in the market and is continuously expanding the label indication for them. Vertex's efforts have been appreciated by the stock market and its stock gained over 121 percent this year so far. It is expected to continue its upward momentum as the company recently reported positive data from an early stage trial for a new indication for its Kalydeco drug. Apart from this, the company's name also frequently comes up as an attractive M&A target, giving an extra push to its stock. Overall, the company shows strong long term potential to perform well, making its stock an attractive option for value investors.
The full post is available to investor members only. Subscribe here.